RecruitingNCT05873231
Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea
Sponsor
Medical University of Graz
Enrollment
150 participants
Start Date
Apr 28, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The role of the gut microbiome in the development of side effects of anti cancer treatment will be assessed in this longitudinal cohort study.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- years or older
- Start of a systemic anti-cancer therapy
- Informed consent
Exclusion Criteria4
- • Pre-existing diarrhoea
- Antibiotic therapy -4 to -1 week before inclusion
- Probiotic treatment -4 to -1 week before inclusion
- Inability to give informed consent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05873231
Related Trials
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
NCT053181961 location
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT055881411 location
Archival of Human Biological Samples in CU-Med Biobank
NCT047064811 location
Small Bowel Capsule Endoscopy in Lynch Syndrome
NCT074726861 location